Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
BCX-10013 by BioCryst Pharmaceuticals for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
BCX-10013 is under clinical development by BioCryst Pharmaceuticals and currently in Phase I for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData,...
Data Insights
BCX-10013 by BioCryst Pharmaceuticals for Glomerulonephritis: Likelihood of Approval
BCX-10013 is under clinical development by BioCryst Pharmaceuticals and currently in Phase I for Glomerulonephritis. According to GlobalData, Phase I...